Somavert and Mobility decreased - a phase IV clinical study of FDA data

Summary:

Mobility decreased is reported as a side effect among people who take Somavert (pegvisomant), especially for people who are female, 60+ old, also take Coumadin, and have Acromegaly.

The phase IV clinical study analyzes which people have Mobility decreased when taking Somavert. It is created by eHealthMe based on reports of 5,769 people who have side effects when taking Somavert from the FDA, and is updated regularly.

What is Somavert?

Somavert has active ingredients of pegvisomant. eHealthMe is studying from 5,774 Somavert users. Check the latest studies of Somavert.

What is Mobility decreased?

Mobility decreased (ability to move is reduced) is found to be associated with 1,776 drugs and 1,636 conditions by eHealthMe. Check the latest studies of Mobility decreased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

5,769 people reported to have side effects when taking Somavert.
Among them, 15 people (0.26%) have Mobility decreased.

Could Somavert cause Mobility decreased?

Among these 15 people:

What is the gender of people who have Mobility decreased when taking Somavert? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Mobility decreased when taking Somavert? *

What are other drugs people take besides Somavert? *

What are other side effects people have besides Mobility decreased? *

Weight Increased: 7 people, 46.67%
Pain: 6 people, 40.00%
Hypotension (abnormally low blood pressure): 5 people, 33.33%
Blindness Unilateral: 4 people, 26.67%
Drug Dependence: 4 people, 26.67%
Dry Eyes (lack of adequate tears): 4 people, 26.67%
Fatigue (feeling of tiredness): 4 people, 26.67%
Weight Decreased: 4 people, 26.67%
Insomnia (sleeplessness): 4 people, 26.67%
Drug Ineffective: 3 people, 20.00%

What are the existing conditions these people have? *

Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 11 people, 73.33%
Gigantism (excessive growth and height): 4 people, 26.67%
Thyroid Mass: 2 people, 13.33%
Sinusitis (inflammation of sinus): 2 people, 13.33%
Pain: 2 people, 13.33%
Micturition Disorder (disease of passing urine): 2 people, 13.33%
Intraocular Pressure Increased: 2 people, 13.33%
Gastric Disorder (disease of stomach): 2 people, 13.33%
Bone Disorder: 2 people, 13.33%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 13.33%

* Approximation only. Some reports may have incomplete information.

Do you take Somavert and have Mobility decreased?

- Check whether Mobility decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Somavert:

Somavert (5,774 reports)

Browse all side effects of Somavert:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Mobility decreased:

Mobility decreased (1,777 drugs)

Browse all the conditions that are associated with Mobility decreased:

Mobility decreased (1,636 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pegvisomant (the active ingredients of Somavert) and Somavert (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.